SecSonar.com

ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

ARS Pharmaceuticals, Inc. (SPRY) is a Biotechnology company based in US with a market capitalization of $908.6M. Revenue declined 5.5% year-over-year and free cash flow was negative at -$171.2M. This page tracks SPRY's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 155 employees · IPO Dec 4, 2020

Valuation

Valuation & price

$7.42 · as of May 17, 2026 · -59.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.95

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$18.35$12.54$6.73Jul 25Dec 25Jul 26Jul 7, 25$17.09Jul 9, 25$17.90Jul 11, 25$17.69Jul 15, 25$17.56Jul 17, 25$18.35Jul 21, 25$17.85Jul 23, 25$18.00Jul 25, 25$17.87Jul 29, 25$17.75Jul 31, 25$17.68Aug 4, 25$17.38Aug 6, 25$17.98Aug 11, 25$16.38Aug 13, 25$15.82Aug 15, 25$14.53Aug 19, 25$13.79Aug 21, 25$14.87Aug 25, 25$13.51Aug 27, 25$13.44Aug 29, 25$11.62Sep 3, 25$10.88Sep 5, 25$10.07Sep 9, 25$10.32Sep 11, 25$10.15Sep 16, 25$9.41Sep 18, 25$9.93Sep 22, 25$9.79Sep 24, 25$9.63Sep 26, 25$9.80Sep 30, 25$10.05Oct 2, 25$10.28Oct 6, 25$10.27Oct 8, 25$11.11Oct 10, 25$11.32Oct 14, 25$10.66Oct 16, 25$10.11Oct 21, 25$9.90Oct 23, 25$9.65Oct 27, 25$9.56Oct 29, 25$8.98Oct 31, 25$8.96Nov 4, 25$8.71Nov 6, 25$8.20Nov 10, 25$8.88Nov 12, 25$8.95Nov 14, 25$8.21Nov 18, 25$7.09Nov 20, 25$6.73Nov 25, 25$9.28Nov 28, 25$9.54Dec 2, 25$9.04Dec 4, 25$9.97Dec 8, 25$10.00Dec 10, 25$10.44Dec 12, 25$10.24Dec 16, 25$10.66Dec 18, 25$9.82Dec 22, 25$11.36Dec 24, 25$11.48Dec 29, 25$11.72Jan 2, 26$11.49Jan 6, 26$11.15Jan 8, 26$10.95Jan 12, 26$11.38Jan 14, 26$11.79Jan 16, 26$10.63Jan 21, 26$10.44Jan 23, 26$10.21Jan 27, 26$10.54Jan 29, 26$10.22Feb 2, 26$10.30Feb 4, 26$10.14Feb 9, 26$9.79Feb 11, 26$9.50Feb 13, 26$8.85Feb 18, 26$9.45Feb 20, 26$9.00Feb 24, 26$9.14Feb 26, 26$9.34Mar 2, 26$9.17Mar 4, 26$9.04Mar 6, 26$9.06Mar 10, 26$8.86Mar 12, 26$8.24Mar 17, 26$8.89Mar 19, 26$8.25Mar 23, 26$7.67Mar 25, 26$7.90Mar 27, 26$8.07Mar 31, 26$8.03Apr 2, 26$8.30Apr 7, 26$8.15Apr 9, 26$8.27Apr 13, 26$8.00Apr 15, 26$8.02Apr 17, 26$8.18Apr 22, 26$8.40Apr 24, 26$8.29Apr 28, 26$7.94Apr 30, 26$8.26May 4, 26$8.83May 6, 26$9.28May 8, 26$8.74May 12, 26$8.63May 14, 26$7.94May 18, 26$7.30May 20, 26$7.80May 22, 26$7.94May 28, 26$9.40Jun 1, 26$9.43Jun 3, 26$8.75Jun 5, 26$8.56Jun 9, 26$9.41Jun 11, 26$9.59Jun 15, 26$9.81Jun 17, 26$9.90Jun 22, 26$9.98Jun 24, 26$10.54Jun 26, 26$8.54Jul 2, 26$8.56
$6.7352-week range$18.35
Loading valuation history…

Fundamentals

Key fundamentals

$908.6M

Market cap

-5.5%

Revenue growth (YoY)

75.8%

Gross margin

-$171.2M

Free cash flow (USD)

-$148M

Net debt

Net cash position

1.7%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$17.8MFY 2021$5.5MFY 2022$1.3MFY 2023$30.0KFY 2024$89.1MFY 2025$84.3M
$0$84.3M

Free cash flow by year

2018 → 2025

FY 2018$-17.3MFY 2019$-19.0MFY 2020$8.2MFY 2021$-17.6MFY 2022$-40.3MFY 2023$-59.4MFY 2024$13.0MFY 2025$-171.2M
-$17.3M-$171.2M

Gross margin by year

2021 → 2025

FY 202196.1%FY 2022-1200.9%FY 2023100.0%FY 202476.9%FY 202575.8%
96.1%75.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 15, 2026 (EPS $-0.61)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 25, 2026Filing
  • 8-K eventEarnings ReleaseMay 15, 2026Filing
  • Quarterly report10-Q FiledMay 15, 2026Filing
  • 8-K eventExecutive Employment AgreementMay 13, 2026Filing

Questions

Frequently asked questions

What is ARS Pharmaceuticals, Inc.'s market cap?

ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $908.6M.

What is SPRY's P/E ratio?

A meaningful P/E ratio is not available for SPRY — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is SPRY's price-to-book (P/B) ratio?

SPRY trades at 7.95 times book value per share.

When did ARS Pharmaceuticals, Inc. last report earnings?

SPRY last reported earnings on May 15, 2026; the next date is not yet scheduled.

Are insiders buying SPRY stock?

SEC Form 4 filings show no open-market insider buys at ARS Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

KURA

Kura Oncology, Inc.

$900.2M

ABUS

Arbutus Biopharma Corporation

$922.5M

JANX

Janux Therapeutics, Inc.

$894.3M

XNCR

Xencor, Inc.

$885.3M

PHAR

Pharming Group N.V.

$942.8M

MGTX

MeiraGTx Holdings plc

$962.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.